精品文档---下载后可任意编辑中性粒细胞减少肿瘤患者抗菌药物应用临床实践指南：美国传染病学会 2024 年更新Alison G. Freifeld,1 Eric J. Bow, 9 Kent A. Sepkowitz, 2 Michael J. Boeckh, 4 James I. Ito,5 Craig A. Mullen,3 Issam I. Raad,6Kenneth V. Rolston,6 Jo-Anne H. Young,7 and John R. Wingard81Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska; 2Department of Medicine, Memorial Sloan-Kettering CancerCenter, New York; 3Department of Pediatrics, University of Rochester Medical Center, Rochester, New York; 4Vaccine and Infectious Disease Division,Fred Hutchinson Cancer Research, Seattle, Washington; 5Division of Infectious Diseases, City of Hope National Medical Center, Duarte, California;6Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D.Anderson Cancer Center, Houston, Texas;7Department of Medicine, University of Minnesota, Minneapolis, Minnesota; 8Division of Hematology/Oncology, University of Florida, Gainesville,Florida; and 9Departments of Medical Microbiology and Internal Medicine, the University of Manitoba, and Infection Control Services, Cancer CareManitoba, Winnipeg, Manitoba, Canada本文更新和扩展了 1997 年首次发表，并于 2024 年第一次更新的美国传染病学会（Infectious Diseases Society of America，IDSA）发热和中性粒细胞减少指南。其目的是用于指导化疗引起的发热和中性粒细胞减少肿瘤患者的抗菌药物使用。抗菌药物研发技术、临床试验结果和大量临床经验的最新进展对指南更新提出了方法和建议。作为对以前 2024年指南的更迭，我们对最有可能从抗细菌、抗真菌和抗病毒预防中获益的肿瘤患者人群制订了更为明确的定义。而且，根据表现出的症状和体征、潜在肿瘤、治疗类型和合并疾病，将中性粒细胞减少患者分为高危或低危感染已成为必不可少的治疗流程。推举将危险分层作为发热和中性粒细胞减少患者的治疗起点。此外，尽管治疗流程仍在不断进展，但侵袭性真菌感染的早期检测还是引起了有关经验性或先...
